ChLIA |
Adalimumab |
TNFα |
Anti-adalimumab coated magnetic particles |
ChLIA |
Anti-Adalimumab |
TNFα |
Adalimumab coated magnetic particles |
ChLIA |
Anti-Adalimumab total |
TNFα |
|
ChLIA |
Certolizumab |
TNFα |
Anti-certolizumab coated magnetic particles |
ChLIA |
Anti-Certolizumab |
TNFα |
Cerolizumab coated magnetic particles |
ChLIA |
Golimumab |
TNFα |
Anti-golimumab coated magnetic particles |
ChLIA |
Anti-Golimumab |
TNFα |
Golimumab coated magnetic particles |
ChLIA |
Etanercept |
TNFα |
Anti-etanercept magnetic coated particles |
ChLIA |
Anti-Etanercept |
TNFα |
Etanercept coated magnetic particles |
ChLIA |
Infliximab |
TNFα |
Anti-infliximab coated magnetic particles |
ChLIA |
Anti-Infiximab |
TNFα |
Infliximab coated magnetic particles |
ChLIA |
Anti-Infliximab Total |
TNFα |
|
ChLIA |
Ocrelizumab |
CD20 |
Anti-ocrelizumab coated magnetic particles |
ChLIA |
Anti-Ocrelizumab |
CD20 |
Ocrelizumab coated magnetic particles |
ChLIA |
Risankizumab |
IL-23 |
Anti-risankizumab coated magnetic particles |
ChLIA |
Anti-Risankizumab |
IL-23 |
Risankizumab coated magnetic particles |
ChLIA |
Rituximab |
CD20 |
Anti-rituximab coated magnetic particles |
ChLIA |
Anti-Rituximab |
CD20 |
Rituximab coated magnetic particles |
ChLIA |
Ustekinumab |
IL-12/1L-23 |
Anti-ustekinumab coated magnetic particles |
ChLIA |
Anti-Ustekinumab |
IL-12/1L-23 |
Ustekinumab coated magnetic particles |
ChLIA |
Vedolizumab |
α4β7 |
Anti-vedolizumab coated magnetic particles |
ChLIA |
Anti-Vedolizumab |
α4β7 |
Vedolizumab coated magnetic particles |
ELISA |
Adalimumab |
TNFα |
Anti-Adalimumab coated microplate wells |
ELISA |
Anti-Adalimumab |
TNFα |
Adalimumab coated microplate wells |
ELISA |
Bevacizumab |
VEGF |
Anti-Bevacizumab coated microplate wells |
ELISA |
Anti-Bevacizumab |
VEGF |
Bevacizumab coated microplate wells |
ELISA |
Certolizumab |
TNFα |
Anti-Certolizumab coated microplate wells |
ELISA |
Anti-Certolizumab |
TNFα |
Cerolizumab coated microplate wells |
ELISA |
Etanercept |
TNFα |
Anti-Etanercept coated microplate wells |
ELISA |
Anti-Etanercept |
TNFα |
Etanercept coated microplate wells |
ELISA |
Golimumab |
TNFα |
Anti-Golimumab coated microplate wells |
ELISA |
Anti-Golimumab |
TNFα |
Golimumab coated microplate wells |
ELISA |
Infliximab |
TNFα |
Anti-Infliximab coated microplate wells |
ELISA |
Anti-Infliximab |
TNFα |
Infliximab coated microplate wells |
ELISA |
Rituximab |
CD20 |
Anti-Rituximab coated microplate wells |
ELISA |
Anti-Rituximab |
CD20 |
Rituximab coated microplate wells |
ELISA |
Secukinumab |
IL-17A |
Anti-Secukinumab coated microplate wells |
ELISA |
Anti-Secukinumab |
IL-17A |
Secukinumab coated microplate wells |
ELISA |
Trastuzumab |
HER2 |
Anti-Trastuzumab coated microplate wells |
ELISA |
Anti-Trastuzumab |
HER2 |
Trastuzumab coated microplate wells |
ELISA |
Ustekinumab |
IL-12/1L-23 |
Anti-Ustekinumab coated microplate wells |
ELISA |
Anti-Ustekinumab |
IL-12/1L-23 |
Ustekinumab coated microplate wells |
ELISA |
Vedolizumab |
α4β7 |
Anti-Vedolizumab coated microplate wells |
ELISA |
Anti-Vedolizumab |
α4β7 |
Anti-Vedolizumab coated microplate wells |